Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (R/R Ph plus ALL): First Report from a Phase 1 Study

被引：0

作者：

Zhang, Jingliao ^{[1
]}

Wang, Junxia ^{[1
]}

Guo, Huanshan ^{[2
]}

Liu, Tianfeng ^{[1
]}

Zhang, Xiaoyan ^{[1
]}

Zhang, Ranran ^{[1
]}

Ruan, Min ^{[1
]}

Chang, Lixian ^{[3
]}

Liu, Xiaoming ^{[1
]}

Ren, Yuanyuan ^{[1
]}

Chen, Xia ^{[1
]}

Wang, Hengbang ^{[4
]}

Chen, Zi ^{[4
]}

Zhang, Yingchi ^{[3
]}

Chen, Yumei ^{[1
]}

Zhang, Li ^{[3
]}

Guo, Ye ^{[1
]}

Liu, Fang ^{[5
]}

Chen, Xiaojuan ^{[5
]}

Zou, Yao ^{[1
]}

Yang, Wenyu ^{[5
]}

Zhai, Yifan ^{[2
,4
]}

Zhu, Xiaofan ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China

[2] Guangzhou Healthquest Pharm Co Ltd, Guangzhou, Peoples R China

[3] CAMS & PUMC, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China

[4] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China

[5] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, Dept Pediat Hematol & Oncol,State Key Lab Expt Hem, Tianjin, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-207035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1443 / 1444

页数：2

共 31 条

[1] Olverembatinib (HQP1351) Enhances Antitumor Effects of Chemotherapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Liang, Eric
Min, Ping
Xiong, Yan
Wu, Bingxing
Yu, Huidan
Yang, Dajun
Zhai, Yifan
BLOOD, 2023, 142
[2] Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
Jabbour, Elias
Koller, Paul B.
Oehler, Vivian G.
Jamy, Omer H.
Mukherjee, Sudipto
Hunter, Anthony M.
Baer, Maria R.
Beck, Joseph T.
Chen, Zi
Guo, Huanshan
Fu, Lei
Men, Lichuang
Wang, Hengbang
Yang, Dajun
Zhai, Yifan
Kantarjian, Hagop
Jiang, Lixin
Wang, Cunlin
BLOOD, 2022, 140
[3] Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study
Wen, Ziyu
Fan, Zhiping
Wang, Qiang
Zhou, Xuan
He, Zherou
Gao, Zicheng
Chen, Hong
Liang, Hanyin
Luo, Dongmei
Liu, Xiaoli
Zhou, Hongsheng
Liu, Qifa
Xu, Na
BLOOD, 2023, 142
[4] Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
Jabbour, Panelelias
Kantarjian, Hagop M.
Koller, Paul B.
Jamy, Omer
Oehler, Vivian G.
Lomaia, Elza
Hunter, Anthony M.
Uspenskaya, Olga
Samarina, Svetlana
Mukherjee, Sudipto
Baer, Maria R.
Zherebtsova, Vera
Shuvaev, Vasily
Turkina, Anna
Davydkin, Igor
Cortes, Jorge
Guo, Huanshan
Chen, Zi
Fu, Lei
Wang, Hengbang
Jiang, Lixin
Wang, Cunlin
Yang, Dajun
Zhai, Yifan
BLOOD, 2023, 142
[5] Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Jabbour, Elias J.
Kantarjian, Hagop
Issa, Ghayas C.
Beck, Joseph Thaddeus
Klisovic, Rebecca B.
Mukherjee, Sudipto
Oehler, Vivian G.
Chen, Zi
Lu, Ming
Fu, Tommy
Jiang, Lixin
Zhai, Yifan
Yang, Dajun
BLOOD, 2021, 138
[6] Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome-positive (Ph plus ) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Stock, Wendy
Martinelli, Giovanni
Stelljes, Matthias
DeAngelo, Daniel J.
Gokbuget, Nicola
Advani, Anjali S.
O'Brien, Susan Mary
Liedtke, Michaela
Merchant, Akil Abid
Cassaday, Ryan Daniel
Wang, Tao
Vandendries, Erik
Marks, David I.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens
Li, Zongru
Ting, Zhao
Hu, Lijuan
Duan, Wenbing
Jiang, Qian
BLOOD, 2023, 142
[8] A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Matloub, Yousif
Gore, Lia
Loh, Mignon L.
Pui, Chin-Hon
Hanley, Michael J.
Lu, Vickie
Leonard, E. Jane
Granier, Muriel
Biondi, Andrea
Silverman, Lewis B.
BLOOD, 2020, 136
[9] Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase
Zoghbi, Marianne
Jabbour, Elias
Haddad, Fadi
Short, Nicholas James
Nasnas, Cedric Christophe
Macaron, Walid
Nasr, Lewis Fady
Jain, Nitin
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Daver, Naval Guastad
Chien, Kelly Sharon
Valero, Yesid Alvarado
Issa, Ghayas C.
Mayor, Ejiroghene
Deen, Wuliamatu
Thankachan, Jennifer
Garris, Rebecca
Ravandi, Farhad
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)
Davids, Matthew S.
Siddiqi, Tanya
Chanan-Khan, Asher
Skarbnik, Alan
Winter, Allison M.
Pagel, John M.
Smith, Carrie
Gabrail, Nashat
Perekhrestenko, Tetiana
Pylypenko, Halyna
Kyselova, Olena
Karpenko, Olena
Popovska, Tetiana
Kriachok, Iryna
Usenko, Hanna
Proidakov, Andrew
Ivanov, Vladimir
Lysa, Tamila
Borisenkova, Elena
Bakirov, Bulat
Lukavetsky, Les
Uspenskaya, Olga
Konstantinova, Tatiana S.
Samoylova, Olga S.
Chen, Zi
Huang, Bo
Li, Mingyu
Ahmad, Mohammad
Mudenda, Boyd
Yang, Dajun
Zhai, Yifan
BLOOD, 2021, 138

← 1 2 3 4 →